OCC
Orthocell Ltd
Director Trades
| Date | Director | Value |
|---|---|---|
| J. Wielen | $100,000 | |
| Michael McNulty | $27,974 | |
| John Van Der Wielen | $57,014 |
Company News
Orthocell Appoints First Canadian Distributor For Remplir Collagen Nerve Wrap
Orthocell (ASX: OCC) has appointed the first Canadian distributor for its innovative Remplir collagen nerve wrap ahead of an official in-country launch next month. The undisclosed distributor reportedly has a wealth of expertise in the nerve, spine, and orthopaedic implant markets, with established links in the nation’s healthcare sector to drive product adoption. Orthocell has secured […]
Orthocell’s Remplir Used by Australian Urologists in Prostate Cancer Surgery
Regenerative medicine company Orthocell (ASX: OCC) has introduced its flagship nerve repair device Remplir to Australian urologists for use in nerve-sparing robotic-assisted radical prostatectomies (RARP). Currently up to 80% of men experience erectile dysfunction and up to 35% suffer from urinary incontinence after radical prostatectomy due to damage of the peripheral nerves in the neurovascular […]
Orthocell Posts Record Full-Year Revenue, Takes Remplir and Striate into New Global Markets
Regenerative medicine company Orthocell (ASX: OCC) has reported a record revenue of $9.19 million for the 12 months to the end of June 2025, underscoring market penetration and sales growth of its flagship nerve repair product Remplir in Australia. The figure was up 35.8% on the previous financial year — boosted by $2.73m revenue in […]
Orthocell’s Remplir nerve repair technology sees first surgical use in US procedure
Regenerative medicine company Orthocell (ASX: OCC) has achieved a major breakthrough in the global development of its Remplir technology with the successful completion of a first surgery in the US. Doctors at a hospital in Ohio used the company’s trademarked nerve repair product in a surgical procedure to repair a foot injury. Remplir, developed for […]
Orthocell appoints first four distributors for Remplir nerve repair technology in the US
Regenerative medicine company Orthocell (ASX: OCC) has appointed the first four US distributors for the company’s flagship nerve repair product Remplir. The move follows regulatory clearance from the US Food and Drug Administration earlier this month, which allowed for immediate distribution into the nation’s US$1.6 billion nerve repair market. The four appointees are experienced nerve […]
Orthocell records first sales of Striate+ dental membrane in new European markets
Orthocell (ASX: OCC) has achieved the first sales of its dental guided bone and tissue regeneration product Striate+ into new markets in Germany, Austria and Switzerland through exclusive global distribution partner BioHorizons Implant Systems, one of the world’s largest dental implant companies. BioHorizons subsidiary BioHorizons Camlog, which is responsible for the marketing and distribution of […]
Orthocell receives regulatory approval for sales of Striate+ dental membrane into Singapore
Orthocell (ASX: OCC) has received regulatory approval from Singapore’s Health Sciences Authority to commence regional sales of its dental membrane product Striate+ for use in guided bone and tissue regeneration applications. The company said its Striate+ global marketing and distribution partner BioHorizons was already established in the Singapore market and would facilitate a fast transition […]
Orthocell looks to enter US market following positive CelGro study results
Regenerative medicine company Orthocell (ASX: OCC) has completed a US FDA regulatory study demonstrating successful bone growth using its proprietary CelGro technology and intends to leverage the results to improve its chances of a successful US market entry. The company said the results left it “well-positioned to gain US approval leading to further commercialisation of CelGro” with […]
Orthocell receives patent for breakthrough CelGro ‘collagen rope’ to treat ACL injuries
Regenerative medicine company Orthocell (ASX: OCC) has been granted a key patent for a 16-year period relating to a potential breakthrough CelGro collagen rope device to enhance the surgical repair of anterior cruciate ligament (ACL) injuries. In a statement to the market, Orthocell said its patent was now approved in Australia, Japan and the US which […]
Orthocell on course to revolutionise nerve regeneration after positive interim clinical results
Regenerative medicine company Orthocell (ASX: OCC) came out of a trading halt this morning with positive interim clinical results for CelGro, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. The current trial is being undertaken with leading Australian orthopaedic nerve specialist Dr Alex O’Beirne […]
Company Videos
No videos found.